Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

For Infection-fighting Cells, a Guideline for Expanding the Troops

By Princeton University | March 12, 2019

T cells are like the special ops forces of the immune system, detecting and killing infected cells. When a new threat is detected, the cells ramp up from just a few sentry cells to a full platoon. But how does the immune system make just the right amount of T cells, when the starting populations of T cells vary?

Now a team from Princeton has provided insight into this question using mathematical modeling. The team found that the most important factors in how T cells expand were the starting amount of infectious agent and the affinity of the cells for that agent. The research, which could help optimize vaccine strategies, was published online last week in the journal Proceedings of the National Academy of Sciences.

The Princeton team became intrigued by this question after a recent study by another team (Quiel, et al.) found that this ramp-up follows a predictable pattern: If the initial number of T cells is small, the ramp-up is large, but if beginning number of T cells is large, the ramp-up is small. This relationship follows a mathematical “power law,” which states that the amount of T cell expansion depends inversely as a power of the initial number of T cells.

“The significance of this observed relationship is that even though the immune system is very complicated and has all sorts of feedback mechanisms, you see a kind of regularity, meaning there is likely to be some sort of simple underlying mechanism at work,” Ned Wingreen, the Howard A. Prior Professor in the Life Sciences, a professor of molecular biology and the Lewis-Sigler Institute for Integrative Genomics, and senior author on the study, said. “Whether you start with 50 or 50,000 cells, the process that is governing their amplification is the same.”

The upshot of this relationship is that, whether there were few or many T cells to begin with, the final number ready to fight infection is neither too large nor too small. This makes sense for the organism fighting the infection, but the Princeton team wondered what is happening in the immune system to make this selective ramp-up possible.

First author Andreas Mayer, associate research scholar in Princeton’s Lewis-Sigler Institute for Integrative Genomics, and the team used mathematical modeling to explore how T cells respond when an infection occurs.

T cells are dotted with receptors capable of detecting bits of infectious agents, known as antigens, on the surface of infected cells. When the T-cell receptors stick to antigens on the surface of these cells, the T cells are spurred to clone themselves to make an infection-fighting army.

Early in a new infection, antigen-presenting cells display lots of antigens on their surfaces, but this presentation wanes over time, especially if the infection is being successfully fought by the immune system.

The team found that these waning levels of antigen provide a simple mechanism which can explain the power-law relationship.

The idea is that T cells amplify at their maximum rate until the decreasing number of antigens means that the T cells are no longer able to find antigens.

“If you start off with a low number of T cells, you get to expand for longer until you reach the decreasing level of antigens,” Mayer said. “But if you start off with a larger number of T cells, then relatively quickly you run out of antigens.” T cells that cannot find antigens eventually stop dividing.

This relationship makes evolutionary sense, Wingreen said, because when the infection is gone, the T cells stop expanding, keeping the immune system from becoming overactive.

The team also looked at another facet of the relationship between T cells and antigen-presenting cells: how strongly the two interact. Their model predicted that cells that stick strongly to the antigen will proliferate for longer: the higher the affinity for the antigen, the larger the final number of cells. The researchers were able to check this prediction by reanalyzing data from another previously published study (Zehn, et al.).

“We are particularly excited that our model can explain multiple phenomenological laws of how T cells expand,” Mayer said. “When we started, we did not expect such a simple mechanism to explain so many disparate observations.”

These relationships suggest lessons for vaccine developers, Wingreen said. Vaccines involve the use of antigens to stimulate the production of immune system cells. Mathematical models may help researchers figure out how much antigen is needed to achieve an optimal immune response.


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE